Adjuvant Systemic Therapy of Colon Cancer
What is your usual adjuvant treatment recommendation for the following colon cancer clinical scenarios?
What is your usual adjuvant treatment recommendation for the following colon cancer clinical scenarios?
What is your usual adjuvant treatment recommendation for the following colon cancer clinical scenarios?
Case 1: Treatment of Stage II colon cancer
Case 1: Treatment of Stage II colon cancer
Case 1: Treatment of Stage II colon cancer
Case 1: Treatment of Stage II colon cancer
Approximately what percentage of your patients with colectomies for colon cancer have a suboptimal number of nodes reported pathologically?
In your practice, what number of lymph nodes do you generally consider should be resected to adequately assess the risk of recurrence for patients with node-negative colorectal cancer?
How likely are you to recommend adjuvant chemotherapy to a 60-year-old, healthy woman with Stage II colon cancer and the following estimated 5-year risks of recurrence?
How likely are you to recommend adjuvant chemotherapy to a 60-year-old, healthy woman with Stage II colon cancer and the following estimated 5-year risks of recurrence?
How likely are you to recommend adjuvant chemotherapy to a 60-year-old, healthy woman with Stage II colon cancer and the following estimated 5-year risks of recurrence?
How likely are you to recommend adjuvant chemotherapy to a 60-year-old, healthy woman with Stage II colon cancer and the following estimated 5-year risks of recurrence?
In your estimation, what percentage of colon cancer patients would choose to receive adjuvant FOLFOX, after hearing a balanced presentation of the potential risks and benefits, if the patient was told that there was a chance that the cancer would recur or relapse and that by taking chemotherapy, that chance of relapse would be reduced to
In your estimation, what percentage of colon cancer patients would choose to receive adjuvant FOLFOX, after hearing a balanced presentation of the potential risks and benefits, if the patient was told that there was a chance that the cancer would recur or relapse and that by taking chemotherapy, that chance of relapse would be reduced to
Approximately what percentage of your patients with Stage II colon cancer receive adjuvant chemotherapy?
Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium and Fluorouracil with or without Bevacizumab in Patients with Resected Stage II Colon Cancer
Case 2: Treatment of Stage III colon cancer
Case 2: Treatment of Stage III colon cancer
Bevacizumab is a reasonable clinical recommendation for the 65-year-old patient in the previous case (woman in average health, T3 tumor in the left descending colon, 15/25 lymph nodes positive).
Have you used bevacizumab off protocol in the adjuvant setting?
The combination of adjuvant FOLFOX and bevacizumab will result in improved disease-free survival compared to FOLFOX alone for patients with resected Stage II or III colon cancer who are enrolled in the NSABP-C-08 trial.
Would you consider including bevacizumab in the adjuvant therapy of a younger, healthy, well-informed patient with high-risk, multiple node-positive colon cancer who requested it and would pay for it?
In general, for otherwise healthy patients of any age — even those in their seventies or eighties — if adjuvant chemotherapy is to be used, it should include oxaliplatin.
Assume you have a patient on an adjuvant oxaliplatin-containing regimen who develops Grade III sensory neurotoxicity after 8/12 planned cycles. Which of the following would likely be your treatment plan?
With the understanding that more data may be required to definitively answer this question, in your best estimation, how would you currently compare XELOX/CAPOX to FOLFOX in the adjuvant setting?
With the understanding that more data may be required to definitively answer this question, in your best estimation, how would you currently compare XELOX/CAPOX to FOLFOX in the adjuvant setting?
Have you used capecitabine with oxaliplatin in the adjuvant setting?
What dose of capecitabine do you routinely use in combination with oxaliplatin in the adjuvant setting?
Practicing oncologists should be discussing with patients the potential impact of exercise and diet on disease recurrence.
Practicing oncologists should be discussing with patients the potential impact of exercise and diet on disease recurrence.
